Official Title
Thymic Function in Patients With COVID-19
Brief Summary

The main clinical manifestation associated with SARS-CoV-2 infection is an influenza-like illness that follows the infection of the respiratory tract. In a few percent of infected people, inflammation of the lungs leads to severe pneumonia that requires hospitalization, in intensive care units for the more severe cases. Despite intensive care, a fatal outcome occurs in 6% and 12% of women and men over 80 years of age hospitalized for severe COVID, respectively. Factors associated with a higher risk of death in patients with SARS-CoV-2 include age and low circulating lymphocyte counts. Significant lymphopenia is indeed frequently observed in patients with severe COVID-19 and both phenotypic and functional changes in antiviral T cells have been correlated with the severity of COVID-19. The thymus, the organ that produces T lymphocytes, undergoes progressive physiological involution with age. However, in the elderly, rare cases of thymic hyperplasia are reported in autoimmune diseases or cancers, or are observed in response to deep lymphopenia, whether or not associated with sepsis. This cohort of patients treated for a SARS-CoV-2 infection could allow to better understand the role of the thymus in this pathology.

Not yet recruiting
COVID19

Genetic: Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region
DNA extraction from blood samples, PCR and Sequencing
Case : COVID-19 positive patients

Biological: Blood sample
Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
Case : COVID-19 positive patients
Control : COVID-19 negative patients

Diagnostic Test: CT Scan
Thymus and lung imaging
Case : COVID-19 positive patients
Control : COVID-19 negative patients

Eligibility Criteria

Inclusion Criteria:

Cases : - Patients with confirmed COVID-19 infection - Hospitalized during the first wave of the SARS-CoV-2 pandemic (march/april 2020) - Having signed a written informed consent form - Affiliation to the social security system

Controls : - Non-COVID-19 patients - Hospitalized for other reasons - Age and sex-matched controls - Having signed a written informed consent form, - Affiliation to the social security system

Exclusion Criteria: - Autoimmune disease - HIV, Hepatitis B or Hepatitis C - Pregnant or breastfeeding women - A mental or linguistic inability to understand the study - Patient under protection of the adults (guardianship, curators or safeguard of justice)

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
France
Contacts

Rémi Cheynier, PhD
0140516541 +33
remi.cheynier@inserm.fr

CMC Ambroise Paré
NCT Number
Keywords
COVID19
Thymic function
GENETIC POLYMORPHISM